Clinical trials
Amyloid clinical trials
Below are recruiting amyloid clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07787169RecruitingPhase 1
Study of amyloid-targeting therapies for Alzheimer's disease
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
Anaheim, CaliforniaAges 18–85 - NCT07130565Recruiting
Pan-Amyloid PET/CT Scan for Amyloid Heart Disease
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
Hefei, AnhuiAges 18–80 - NCT06933212Recruiting
Mediterranean diet for CADASIL and CAA
This trial is testing whether a Mediterranean diet (rich in fruits, vegetables, whole grains, and healthy fats) can help people with CADASIL or cerebral amyloid angiopathy (CAA) — two conditions that affect blood vessels in the brain. If you have one of these diagnoses, the study may help you understand how diet can support your brain health.
MilanAges 18 years+ - NCT06725706Recruiting
Beta-amyloid PET scan for amyloid-related diseases
This trial is testing whether a special scan (beta-amyloid PET/CT) can help detect abnormal protein clumps in the brain that are linked to certain diseases, including cancer. The scan might help doctors better understand and track these conditions.
Hefei, AnhuiAges 18–80 - NCT06421532Enrolling by invitationPhase 2
Testing LXB to clear protein buildup in CAA
This study tests whether the drug LXB (sodium oxybate) can help clear abnormal protein buildup in the brain's small blood vessels (CAA). Participants will take LXB nightly for 8 weeks and have MRIs and spinal taps to measure changes.
LeidenAges 30 years+ - NCT05734378Recruiting
Study aims to predict outcomes in small blood vessel brain disease
This trial is looking at how brain “small blood vessel disease” changes over time and what outcomes to expect. If you have certain symptoms or scan findings from this condition, your care team may compare your prognosis to help guide future treatment planning.
BernAges 16 years+ - NCT07791160Recruiting
A study of acoramidis for people with transthyretin amyloid cardiomyopathy
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
Many LocationsAges 18 years+ - NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT06864000Recruiting
Genetic study of a brain condition called CAA
This study looks at the genetic causes of cerebral amyloid angiopathy (CAA), a condition where proteins build up in small brain blood vessels. It aims to better understand the disease and may help guide future treatments.
RouenAges 18–99 - NCT07250035RecruitingPhase 3
Chinese herb trial for brain bleed linked to amyloid angiopathy
This trial tests a traditional Chinese medicine called Jiedu Huayu to see if it helps people recover from a brain bleed caused by a condition where proteins build up in blood vessel walls (cerebral amyloid angiopathy). The goal is to improve outcomes without surgery.
BeijingAges 50–90 - NCT07240844RecruitingPhase 4
Enavogliflozin for amyloid heart disease
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
SeoulAges 19 years+ - NCT07235462Recruiting
Acoramidis for heart disease due to TTR amyloidosis
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
Multiple LocationsAges 18 years+ - NCT07222930Enrolling by invitation
Learning about amyloid and tau test results
This study helps people understand their results from brain scans that measure amyloid and tau proteins, which are linked to Alzheimer's disease. It is for adults 45 and older who are part of specific Alzheimer's research programs and have no dementia diagnosis.
Madison, WisconsinAges 45–89 - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07196839Recruiting
Study of heart medication and amyloid levels over time
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Dallas, TexasAges 30–80 - NCT07041450Recruiting
Screening for Alzheimer's treatment using digital tests and blood tests
This study is testing whether simple digital memory tests and blood tests can help find people who might qualify for anti-amyloid treatments (medications that target Alzheimer's-related proteins). It aims to make screening easier and faster, without needing a spinal tap or PET scan.
Greenfield Park, QuebecAges 55–90 - NCT07026994RecruitingPhase 2
Colchicine to prevent another brain bleed from CAA
This trial tests if colchicine can reduce the risk of another stroke caused by bleeding in the brain due to a condition called cerebral amyloid angiopathy (CAA). You may qualify if you've recently had a brain bleed from CAA and have certain signs on brain scans.
BeijingAges 55 years+ - NCT06974877RecruitingPhase 1
PET/CT Imaging for Amyloid in CAPS on Anakinra
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
Bethesda, MarylandAges 18–120 - NCT06634108RecruitingPhase 1/Phase 2
Genistein for heart failure from ATTR amyloid cardiomyopathy
This trial tests whether genistein, a plant-based supplement, can help people with a specific type of heart disease called ATTR amyloid cardiomyopathy. You might join if you have heart failure with reduced pumping function and this rare protein condition.
London, OntarioAges 40–80 - NCT06940336RecruitingPhase 4
Testing tafamidis for transthyretin amyloid polyneuropathy
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
JinanAges 18–80 - NCT06714097Recruiting
Digital twin technology for stroke and related conditions
This trial tests a digital twin system to help prevent a second stroke or brain bleed in people with stroke, Moyamoya disease, or cerebral amyloid angiopathy. The system uses your medical data to create a virtual copy of you, which doctors can use to plan your care.
Milan, MichiganAges 18 years+ - NCT06672237RecruitingPhase 3
Study of NTLA-2001 for hereditary ATTR amyloidosis with nerve damage
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
Buenos AiresAges 18–85 - NCT05999084Enrolling by invitation
Georgia Memory Net Anti-Amyloid Antibody Study
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
Albany, GeorgiaAges 50–90 - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloid?
- Yes. Clin2 currently lists 89 recruiting amyloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.